William Jacob Savage Sells 7,378 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider William Jacob Savage sold 7,378 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $65.88, for a total value of $486,062.64. Following the completion of the transaction, the insider owned 85,211 shares in the company, valued at $5,613,700.68. This trade represents a 7.97% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

William Jacob Savage also recently made the following trade(s):

• On Tuesday, February 17th, William Jacob Savage sold 3,256 shares of Disc Medicine stock. The shares were sold at an average price of $62.86, for a total transaction of $204,672.16.
• On Monday, December 15th, William Jacob Savage sold 13,093 shares of Disc Medicine stock. The shares were sold at an average price of $91.22, for a total transaction of $1,194,343.46.

Disc Medicine Trading Down 5.1%

Shares of Disc Medicine stock traded down $3.26 during mid-day trading on Wednesday, hitting $61.10. 643,077 shares of the stock were exchanged, compared to its average volume of 746,011. The company has a 50-day simple moving average of $73.86 and a 200 day simple moving average of $75.69. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine, Inc. has a twelve month low of $30.82 and a twelve month high of $99.50. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of -10.20 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The business had revenue of ($19.88) million for the quarter, compared to analyst estimates of $0.15 million. Research analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on IRON shares. Cantor Fitzgerald reduced their price objective on Disc Medicine from $153.00 to $125.00 and set an “overweight” rating for the company in a research note on Tuesday, February 17th. Wedbush cut their target price on Disc Medicine from $110.00 to $88.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Stifel Nicolaus dropped their price objective on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. TD Cowen reiterated a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th. Finally, Truist Financial lowered their target price on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $104.80.

Institutional Investors Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently added to or reduced their stakes in IRON. ANTIPODES PARTNERS Ltd bought a new position in Disc Medicine during the fourth quarter worth $33,000. Aster Capital Management DIFC Ltd bought a new position in shares of Disc Medicine in the 3rd quarter valued at $38,000. CWM LLC grew its stake in shares of Disc Medicine by 213.5% in the second quarter. CWM LLC now owns 1,044 shares of the company’s stock worth $55,000 after purchasing an additional 711 shares during the last quarter. KBC Group NV acquired a new stake in shares of Disc Medicine during the fourth quarter worth $80,000. Finally, Avanza Fonder AB grew its holdings in Disc Medicine by 54.0% in the third quarter. Avanza Fonder AB now owns 1,668 shares of the company’s stock worth $110,000 after purchasing an additional 585 shares during the period. 83.70% of the stock is owned by institutional investors.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.